Hongqing Zhang, NP
Nurse Practitioner · San Jose
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 2
- 1 carrier
- Office
- 1
- Since medical school
- 8 years
- Graduated 2018
Offices
1 location · County of Santa Clara · 1,000 clinicians in this group
Looking this up.
Hospitals listed: Santa Clara Valley Medical Center. That is not proof they admit you there this week.
Plans that list them
2 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Hongqing Zhang’s office at (408) 885-5000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Santa Clara Valley Medical CenterSan Jose, CAAcute Care Hospital · Government - Local · Has an emergency department · Birthing-friendlyPart of Santa Clara Valley Health and Hospital System, which runs 3 hospitalsPatients rate it 3 of 5 · 70% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — SSI - Colon Surgery: 2.572, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.563, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.256, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.369, Oct 2024 – Sep 2025
See every measure and the patient survey for Santa Clara Valley Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 1 worse of 8 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| SSI - Colon SurgeryInfections | 2.572 | Worse | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.563 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.256 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.369 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.25 (0.3 to 2.2) · 1,535 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.07 (0.76 to 1.38) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 214.59 (167.38 to 261.8) · 108 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.8 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6 · 141 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.2 · 124 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.3 · 501 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.9 · 653 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 348 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 4,502 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.24 (0.04 to 0.43) · 9,014 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.34 (0.15 to 0.52) · 9,216 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.54 (2.51 to 6.58) · 1,421 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.54 (0 to 3.2) · 288 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,446 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.61 (4.09 to 19.14) · 294 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.29 (3.39 to 11.2) · 299 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.9 (0.45 to 3.36) · 333 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.23 (0 to 0.78) · 7,538 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 5.4 · 94 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.735 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 2.573 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.6 · 185 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 951 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 56.3 · 128 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 6.4 · 644 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 1.3 · 699 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.3 · 921 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (3.9 to 8.1) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.6 (9.4 to 16.5) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 94 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.4 · 54 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 242 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.2 (9.9 to 17.4) · 702 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 195 cases | No different | Jan 2024 – Dec 2024 |
What patients said (4,032 patients answered, 29% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 2 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 70% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 82% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 71% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 69% |
| Nurses "always" treated them with courtesy and respect | 80% |
| "Always" quiet at night | 43% |
| "YES", patients would definitely recommend the hospital | 70% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
Original Medicare doctor bills
$6,034
Medicare paid this office $6,034 for 71 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Screening mammography | 39 | $5,044 | $129 |
| Short return visit (20+ min) | 15 | $392 | $26 |
| Return visit (30+ min) | 15 | $376 | $25 |
Who their Medicare patients are
71 Original Medicare patients in 2024. Average age 71 · Women 79% · Also on Medicaid 63% · Health risk score 1.64. Above the middle of the specialty; the typical nurse practitioner clinician is at 1.42.
Conditions among them: High blood pressure 75% · Chronic kidney disease 54% · Diabetes 48% · Depression 23% · Coronary heart disease 18% · Heart failure 18% · Atrial fibrillation 17%.
The office billed $36,584, Medicare allowed $7,339 and paid $6,034; for 71 services of 5 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 71 | 71 | 71 | 1.64 | $36,584 | $6,034 |
| 2023 | 63 | 104 | 74 | 2.51 | $14,365 | $2,998 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 2 services
| Short return visit (20+ min) | 27 | $784 | $27 |
| Return visit (30+ min) | 26 | $724 | $27 |
Medicaid work
$12,416 in 2024
Medicaid paid $12,416 for 172 billed services this clinician did in 2024, up to 19 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Clinic visit/encounter, all-inclusive | 87 | $12,416 |
| Short return visit (20+ min) | 85 | $0 |
| 2024 | 172 | 2 | 19 | $12,416 |
| 2023 | 292 | 2 | 44 | $27,859 |
| 2022 | 1,052 | 3 | 67 | $93,692 |
| 2021 | 1,349 | 4 | 72 | $115,213 |
| 2020 | 1,265 | 6 | 77 | $108,188 |
| 2019 | 623 | 3 | 67 | $65,721 |
See the largest Medicaid services in earlier years
2023
| Clinic visit/encounter, all-inclusive | 171 | $27,859 |
| Short return visit (20+ min) | 121 | $0 |
2022
| Clinic visit/encounter, all-inclusive | 603 | $93,692 |
| Short return visit | 14 | $0 |
| Short return visit (20+ min) | 435 | $0 |
2021
| Clinic visit/encounter, all-inclusive | 749 | $114,765 |
| Short return visit (20+ min) | 563 | $284 |
| COMPREHENSIVE METABOLIC PANEL | 12 | $165 |
| Return visit (30+ min) | 25 | $0 |
2020
| Clinic visit/encounter, all-inclusive | 712 | $107,578 |
| Blood test, lipids (cholesterol and triglycerides) | 13 | $242 |
| COMPREHENSIVE METABOLIC PANEL | 14 | $206 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 15 | $163 |
| Short return visit (20+ min) | 493 | $0 |
| Return visit (30+ min) | 18 | $0 |
2019
| Clinic visit/encounter, all-inclusive | 435 | $65,721 |
| Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]), qualitative or semiquantitative; respiratory syncytial virus | 13 | $0 |
| Short return visit (20+ min) | 175 | $0 |
Drugs they prescribed that Part D paid
$28,622
Pharmacies billed $28,622 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 140) in 2024. At or below the middle of the specialty; the typical nurse practitioner clinician is at 0%.
112 generic and 28 brand-name prescriptions · $28,622 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Hydralazine | 13 | $119 | $9 |
| Furosemide | 11 | $87 | $8 |
Year by year
| 2024 | 140 | 36 | 0% (0) | 20% | $28,622 |
| 2023 | 238 | 65 | 0% (0) | None | $57,519 |
| 2022 | 295 | 68 | None | None | $68,406 |
| 2021 | 362 | 79 | 3% (11) | None | $42,864 |
| 2020 | 317 | 67 | 0% (0) | None | $29,215 |
| 2019 | 69 | 12 | 0% (0) | None | $4,412 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 3 drugs
| Rybelsus | 13 | $12,778 | $983 |
| Bumetanide | 11 | $425 | $39 |
| Amlodipine Besylate | 23 | $273 | $12 |
2022: 10 drugs
| Rybelsus | 15 | $14,305 | $954 |
| Sevelamer Carbonate | 11 | $8,509 | $774 |
| Bumetanide | 12 | $1,551 | $129 |
| Calcium Acetate | 15 | $1,013 | $68 |
| Febuxostat | 12 | $691 | $58 |
| Lisinopril | 12 | $262 | $22 |
| Metoprolol | 12 | $255 | $21 |
| Amlodipine Besylate | 12 | $155 | $13 |
| Furosemide | 22 | $145 | $7 |
| Omeprazole | 13 | $97 | $7 |
2021: 9 drugs
| Tradjenta | 14 | $8,237 | $588 |
| Sevelamer Carbonate | 14 | $2,335 | $167 |
| Calcium Acetate | 19 | $1,155 | $61 |
| Atorvastatin | 18 | $200 | $11 |
| Gabapentin | 12 | $166 | $14 |
| Amlodipine Besylate | 21 | $98 | $5 |
| Omeprazole | 11 | $79 | $7 |
| Lisinopril | 11 | $73 | $7 |
| Tramadol | 11 | $26 | $2 |
2020: 7 drugs
| Tradjenta | 11 | $8,052 | $732 |
| Albuterol Sulfate Hfa | 14 | $558 | $40 |
| Metformin | 29 | $165 | $6 |
| Atorvastatin | 21 | $118 | $6 |
| Losartan | 11 | $106 | $10 |
| Lisinopril | 32 | $101 | $3 |
| Amlodipine Besylate | 19 | $64 | $3 |
2019: 1 drug
| Lisinopril | 11 | $59 | $5 |
Money from drug and device companies
$30 in 2024
| 2024 | 1 | 1 | None | $30 |
| 2023 | 10 | 10 | None | $766 |
| 2022 | 5 | 6 | None | $522 |
| 2021 | 4 | 7 | None | $504 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Amgen | Epogen | $30 | 1 payment
|
See the published payment
| Amgen | Meals · 2024-03-06 | Epogen | $30 |
See earlier years (2023, 2022, 2021)
2023: $766
| Gilead Sciences | None | $125 | 1 payment
|
| Neurocrine Biosciences | Ingrezza | $125 | 1 payment
|
| Genzyme | Dupixent | $123 | 1 payment
|
| Novo Nordisk | Wegovy | $122 | 1 payment
|
| Otsuka America Pharmaceutical | Jynarque | $110 | 1 payment
|
| Abbvie | None | $75 | 1 payment
|
| Amgen | Epogen | $26 | 1 payment
|
| Vifor Pharma | Veltassa | $24 | 1 payment
|
| Kyowa Kirin | None | $19 | 1 payment
|
| Travere Therapeutics | None | $18 | 1 payment
|
2022: $522
| Abbvie | Skyrizi | $240 | 2 payments
|
| Novo Nordisk | Saxenda | $125 | 1 payment
|
| AVEO Pharmaceuticals | Fotivda | $125 | 1 payment
|
| Bayer HealthCare Pharmaceuticals | Kerendia | $16 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $16 | 1 payment
|
2021: $504
| AbbVie | Venclexta | $238 | 3 payments
|
| Bayer HealthCare Pharmaceuticals | Kerendia | $125 | 1 payment
|
| Fresenius USA Marketing | Velphoro | $120 | 2 payments
|
| GlaxoSmithKline | Benlysta | $20 | 1 payment
|
Professional record
- NPI
- 1114481041
- Licence
- CA NP95010162
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 363LF0000X (363LF0000X)
- Mailing address
- 321 1st St, Hollister, CA, 95023
- NPI first listed
- 2019-01-24
- NPI last updated
- 2019-01-24
This is when the NPI record was last certified, not a medical board exam.